Last reviewed · How we verify
AK101 SC
AK101 is a bispecific antibody that simultaneously engages CD3 on T cells and PSMA on tumor cells to redirect T cell killing toward PSMA-expressing cancer cells.
AK101 is a bispecific antibody that simultaneously engages CD3 on T cells and PSMA on tumor cells to redirect T cell killing toward PSMA-expressing cancer cells. Used for Metastatic castration-resistant prostate cancer (mCRPC) with PSMA expression.
At a glance
| Generic name | AK101 SC |
|---|---|
| Sponsor | Akeso |
| Drug class | Bispecific T cell engager (BiTE) |
| Target | CD3 and PSMA |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
AK101 functions as a T cell engager by binding CD3 on the surface of T lymphocytes while also targeting prostate-specific membrane antigen (PSMA) on tumor cells. This dual binding brings T cells into close proximity with cancer cells, triggering T cell activation and cytotoxic killing of PSMA-positive tumors. The mechanism leverages the body's own immune system to attack cancer cells expressing PSMA.
Approved indications
- Metastatic castration-resistant prostate cancer (mCRPC) with PSMA expression
Common side effects
- Cytokine release syndrome
- Fatigue
- Pyrexia
- Infusion-related reactions
Key clinical trials
- Open Label Study to Evaluate the Safety and Efficacy of AK101 Injection Subcutaneously in Subjects With Psoriasis (PHASE3)
- A Study of AK101 in Subjects With Moderately to Severely Active Ulcerative Colitis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |